The KRAS Mutation Analysis Assay is a real-time PCR-based assay designed to detect somatic mutations in exons 2, 3 and 4 of the KRAS gene. This assay is designed to detect the following KRAS mutations: Exon 2 - G12C, G12A/D/R/V/S and G13D; Exon 3 - A59E/G/T and Q61H/L/R; Exon 4 - K117N/R/E and A146T/P/V. Testing is available separately or in combination with BRAF, HRAS and NRAS in the RAS/RAF Panel.
KRAS mutations are frequently found in many human cancers, particularly non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic cancer. KRAS mutations occur most commonly in hotspots at codons 12 and 13 of exon 2. KRAS G12C mutation in NSCLC patients may predict response to targeted RAS GTPase inhibitors including sotorasib and adagrasib. CRC patients with any known KRAS mutation (exons 2, 3, and 4) are associated with resistance to anti-EGFR targeted antibody therapies such as cetuximab or panitumumab with the exception as part of a regimen targeting a KRAS G12C mutation.
- FFPE solid tumor tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.
7 days